Literature DB >> 18632772

Protecting axons in multiple sclerosis.

A Wilkins1, N Scolding.   

Abstract

Typically patients with multiple sclerosis (MS) experience acute episodes of neurological dysfunction, which recover followed, at a later stage, by slow and insidious accumulation of disability (disease progression). Disease progression reflects axon damage and loss within the central nervous system. However, the precise mechanism of axon injury in MS is not clear. Inflammation occurring during acute relapses undoubtedly causes some degree of acute axon damage, but epidemiological data and treatment studies have suggested that inflammation alone is not the sole cause of axonopathy. Indeed, there appears to be dissociation between inflammation and disease progression once a certain level of clinical disability has been reached because immune suppression in patients who have established disease progression does not halt the slow decrease of function. The slow and insidious loss of neurological function that occurs during the progressive phase of the disease implies a degenerative process. Whether axon drop-out occurs at these later stages because of previous inflammatory damage to axons; because of low grade inflammation causing damage to already vulnerable demyelinated axons; because of loss of trophic environment for axons to survive; or as part of a completely independent neurodegenerative process is not clear. Understanding disease mechanisms involved in the axonopathy of MS allows for the development of rational therapies for disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 18632772     DOI: 10.1177/1352458508091370

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features.

Authors:  Mingqiang Xie; Jennifer E Tobin; Matthew D Budde; Chin-I Chen; Kathryn Trinkaus; Anne H Cross; Dennis P McDaniel; Sheng-Kwei Song; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

Review 2.  Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation.

Authors:  David P Stirling; Peter K Stys
Journal:  Trends Mol Med       Date:  2010-03-06       Impact factor: 11.951

3.  Role of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis.

Authors:  Chan Chen; Jie-Zhong Yu; Qiong Zhang; Yong-Fei Zhao; Chun-Yun Liu; Yan-Hua Li; Wan-Fang Yang; Cun-Gen Ma; Bao-Guo Xiao
Journal:  Neuromolecular Med       Date:  2015-10-19       Impact factor: 3.843

Review 4.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

5.  β2-adrenergic receptor and astrocyte glucose metabolism.

Authors:  Jun-hong Dong; Xin Chen; Min Cui; Xiao Yu; Qi Pang; Jin-peng Sun
Journal:  J Mol Neurosci       Date:  2012-03-08       Impact factor: 3.444

Review 6.  Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis?

Authors:  Miguel D'haeseleer; Stéphanie Hostenbach; Ilse Peeters; Souraya El Sankari; Guy Nagels; Jacques De Keyser; Marie B D'hooghe
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-24       Impact factor: 6.200

7.  Multiple sclerosis: preventing progression and disability in MS-when to treat?

Authors:  Maura Pugliatti
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

8.  Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis.

Authors:  M B D'hooghe; P Haentjens; G Nagels; T D'Hooghe; J De Keyser
Journal:  J Neurol       Date:  2011-10-13       Impact factor: 4.849

9.  Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.

Authors:  Jing-Wen Yu; Yan-Hua Li; Guo-Bin Song; Jie-Zhong Yu; Chun-Yun Liu; Jian-Chun Liu; Hai-Fei Zhang; Wan-Fang Yang; Qing Wang; Ya-Ping Yan; Bao-Guo Xiao; Cun-Gen Ma
Journal:  J Mol Neurosci       Date:  2016-08-30       Impact factor: 3.444

10.  Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1.

Authors:  Miguel D'haeseleer; Roel Beelen; Yves Fierens; Melissa Cambron; Anne-Marie Vanbinst; Christian Verborgh; Johan Demey; Jacques De Keyser
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.